used Bristol, an Nrf2 inhibitor, in the AML human cell lines (HL60, Molm13, THP-1, and U937) along with Cytarabine (Ara-C) and Daunorubicin (Dnr), to decrease drug resistance and enhance apoptosis in AML cells. This evidence concerns the gene NFE2L2 and acute myeloid leukemia.